Buscar
03/08/2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Macaulay V.M., Lord S., Hussain S., Maroto J.P., Jones R.H., Climent M.Á., Cook N., Lin, CC, Wang, SS, Bianchini D., Bailey M., Schlieker L., Bogenrieder T., de Bono J.. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6)DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6.400(Q1/2D).
01/08/2023
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).
01/08/2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Grunwald, V, Powles, T, Kopyltsov, E, Kozlov, V, Alonso-Gordoa, T, Eto, M, Hutson, T, Motzer, R, Winquist, E, Maroto, P, Keam, B, Procopio, G, Wong, SR, Melichar, B, Rolland, F, Oya, M, Rodriguez-Lopez, K, Saito, K, McKenzie, J, Porta, C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4)DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8.300(Q1/1D).
01/08/2023
The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria
Mayayo-Vallverdu, C, de Heredia, ML, Prat, E, Gonzalez, L, Guarch, ME, Vilches, C, Munoz, L, Asensi, MA, Serra, C, Llebaria, A, Casado, M, Artuch, R, Garrabou, G, Garcia-Roves, PM, Pallardo, FV, Nunes, V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10.700(Q1/1D).
01/07/2023
Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
Canto, E, Anguera, G, Jimenez, N, Mellado, B, Ramirez, O, Mariscal, A, Maroto, P, Vidal, S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13)DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3.000(Q1/2D).
06/06/2023
Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques
Giménez-Capitán A., Sánchez-Herrero E., de Lope, LR, Aguilar-Hernández A., Sullivan I., Calvo V., Moya-Horno I., Viteri S., Cabrera C., Aguado C., Armiger N., Valarezo J., Mayo-de-las-Casas C., Reguart N., Rosell R., Provencio M., Romero A., Molina-Vila M.A.. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9)DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5.000(Q1/3D).
05/06/2023
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023)
Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, T, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03229-y. PMID:37273149. IF:2.800(Q2/5D).
04/06/2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Tsuboi M., Herbst R.S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J.W., Lu S., Su, WC, De Marinis F., Shepherd F.A., Lee K.H., Le N.T., Dechaphunkul A., Kowalski D., Poole L., Bolanos A., Rukazenkov Y., Wu, YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2)DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96.300(Q1/1D).